Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 618

Results For "IP"

10477 News Found

Novartis receives European approval for Cosentyx
Drug Approval | June 03, 2023

Novartis receives European approval for Cosentyx

European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5


AstraZeneca receives CDSCO approval for Tremelimumab combination in India
Drug Approval | June 02, 2023

AstraZeneca receives CDSCO approval for Tremelimumab combination in India

Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)


Evonik launches next-generation peptide for biopharma applications
News | June 02, 2023

Evonik launches next-generation peptide for biopharma applications

One thousand times more soluble than L-cystine at neutral pH


Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
Clinical Trials | June 02, 2023

Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options

Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone


Merck partners with California-based research group to study catalysis innovation through machine learning
News | June 02, 2023

Merck partners with California-based research group to study catalysis innovation through machine learning

Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques


Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy
News | June 02, 2023

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada


Lonza acquires biotech firm Synaffix
News | June 02, 2023

Lonza acquires biotech firm Synaffix

Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology


Honeywell refurbishes PHCs in rural India across three states
Healthcare | June 01, 2023

Honeywell refurbishes PHCs in rural India across three states

The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana


Laurus Labs to increase stake in ImmunoACT to 33.86%
News | June 01, 2023

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19


USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada
Drug Approval | June 01, 2023

USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada

The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.